Apyx Medical (APYX) Current Deferred Revenue (2019 - 2025)

Apyx Medical has reported Current Deferred Revenue for 7 years, with the latest figure at $1.7 million in Q4 2025.

• For the quarter ending Q4 2025, Current Deferred Revenue fell 15.0% year-over-year to $1.7 million; the trailing twelve-month figure through Dec 2025 stood at $1.7 million (down 15.0% YoY), and the FY2025 full-year result was $1.7 million, down 15.0% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $1.7 million, down from $2.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $2.3 million in Q4 2022, with the low at $1.7 million in Q4 2023.
• Historically, Current Deferred Revenue has averaged $1.9 million across 5 years, with a median of $1.9 million in 2021.
• Annual changes were most pronounced in 2021 — Current Deferred Revenue soared 216.67% — and 2023, when it declined 26.09%.
• Apyx Medical's Current Deferred Revenue stood at $1.9 million in 2021, then grew by 21.05% to $2.3 million in 2022, then dropped by 26.09% to $1.7 million in 2023, then increased by 17.65% to $2.0 million in 2024, then fell by 15.0% to $1.7 million in 2025.
• The last three Current Deferred Revenue figures came in at $1.7 million (Q4 2025), $2.0 million (Q4 2024), and $1.7 million (Q4 2023), per Business Quant data.